- Home
- CRDF vs TLPH Comparison
CRDF vs TLPH Comparison
Compare CRDF & TLPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDF | TLPH |
|---|---|---|
| Founded | 1999 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 82.5M | 70.3M |
| IPO Year | 2012 | 2010 |
Fundamental Metrics
Financial Performance| Metric | CRDF | TLPH |
|---|---|---|
| Price | $1.09 | $1.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | ★ $5.81 | $3.13 |
| AVG Volume (30 Days) | ★ 746.3K | 148.3K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $365,993.00 | ★ $2,151,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.70 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 49.61 | N/A |
| 52 Week Low | $0.76 | $0.69 |
| 52 Week High | $3.31 | $1.57 |
Technical Indicators
Market Signals| Indicator | CRDF | TLPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.03 | 35.90 |
| Support Level | $0.88 | $0.76 |
| Resistance Level | $1.13 | $1.13 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 10.45 | 25.00 |
Price Performance
Historical ComparisonAbout CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
About TLPH Talphera Inc.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.